TNDM — Tandem Diabetes Care Income Statement
0.000.00%
Last trade - 00:00- $2.20bn
- $2.02bn
- $747.72m
- 62
- 21
- 88
- 58
Annual income statement for Tandem Diabetes Care, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 362 | 499 | 703 | 801 | 748 |
| Cost of Revenue | |||||
| Gross Profit | 194 | 261 | 376 | 413 | 368 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 379 | 507 | 680 | 894 | 981 |
| Operating Profit | -16.7 | -7.96 | 22.7 | -92.8 | -233 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -24.6 | -36.3 | 15.9 | -92.9 | -220 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -24.8 | -34.4 | 15.6 | -94.6 | -223 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -24.8 | -34.4 | 15.6 | -94.6 | -223 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -24.8 | -34.4 | 15.6 | -94.6 | -223 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.423 | -0.564 | 0.242 | -1.42 | -3.31 |